Small bowel capsule endoscopy is the dominating segment, accounting for 54.6% of global revenues in 2024. Its leadership is attributed to its unmatched efficacy in diagnosing conditions like Crohn’s disease and obscure gastrointestinal bleeding (OGIB), which are often difficult to reach via traditional endoscopy.
Obscure Gastrointestinal Bleeding (OGIB) is the leading application, capturing a 45.4% revenue share in 2024. Capsule endoscopy has become the global gold standard for identifying bleeding sources within the small intestine that conventional diagnostic tools cannot easily access.
The Asia-Pacific region is anticipated to register the fastest CAGR. This growth is driven by a large patient pool, increasing incidences of gastrointestinal cancers, rising healthcare expenditures, and significant infrastructure investments in countries like China, India, and South Korea.
AI is a major growth driver used to automate the detection of lesions, polyps, and bleeding. Recent developments, such as Olympus Corporation’s AI-integrated capsules, aim to reduce diagnostic time and interpretation errors while enhancing accuracy for complex conditions like Crohn’s disease.
The market faces challenges in developing regions due to the high cost of advanced capsule devices and procedures. Additionally, limited reimbursement policies and a lack of specialized physician training in parts of Latin America, Asia-Pacific, and Africa restrict broader patient adoption.
The small intestine tumor application is poised for the fastest growth. This is driven by an increasing global emphasis on early cancer detection and the development of high-resolution imaging and AI-assisted tools that can identify rare but clinically significant tumors.
In 2024, Medtronic debuted the PillCam SB 3 with adaptive frame rate technology, and IntroMedic Co., Ltd. received FDA clearance for the MiroCam-oesophageal capsule. These innovations focus on improving lesion detection, battery life, and diagnostic efficiency.
Telemedicine is creating new growth avenues through remote monitoring solutions, such as Medtronic’s PillCam SB3 @HOME. These programs allow patients to undergo diagnostic procedures in their own homes, addressing the shortage of gastroenterologists and increasing accessibility in underserved regions.
The market is led by prominent medical technology companies, including Medtronic plc, Olympus Corporation, IntroMedic Co., Ltd., Chongqing Jinshan Science & Technology Group Co., Ltd., and Fujifilm Holdings Corporation.
